Hajos S E, Alvarez E, Pierangeli S, Pasqualini C D, Margni R A
Vet Immunol Immunopathol. 1984 Aug;7(1):53-63. doi: 10.1016/0165-2427(84)90027-8.
An experimental model was used in which AKR lymphoma cells (L15) were conditioned to grow in BALB/c mice leading to tumour-bearing (progressor) and tumour-rejecting (regressor) animals. The behaviour of antibodies present in the sera of these animals was studied using as antigen L15 cells or a soluble tumour-associated antigen TEs. Both sera showed similar IIF and haemagglutinating activity. However differences were observed for the complement cytotoxicity assay. Regressor serum as well as a rabbit anti-tumour-associated antigen serum were strongly cytotoxic for the AKR lymphoma cells while progressor serum showed markedly lower activity. Specific antibodies against the tumour-associated antigen were purified. In both sera they were located mainly in IgG1 but also in IgG2. The purified antibodies agglutinated specifically sensitized sheep erythrocytes and reacted by indirect immunofluorescence with L15 cells but not with AKR thymocytes. It is suggested that two qualitatively different humoral immune responses are involved in the mechanisms leading to tumour enhancement or rejection.
使用了一种实验模型，其中将AKR淋巴瘤细胞（L15）进行预处理，使其能在BALB/c小鼠体内生长，从而产生荷瘤（进展型）和肿瘤排斥（消退型）动物。使用L15细胞或可溶性肿瘤相关抗原TEs作为抗原，研究了这些动物血清中存在的抗体的行为。两种血清显示出相似的间接免疫荧光和血凝活性。然而，在补体细胞毒性试验中观察到了差异。消退型血清以及兔抗肿瘤相关抗原血清对AKR淋巴瘤细胞具有强烈的细胞毒性，而进展型血清的活性则明显较低。针对肿瘤相关抗原的特异性抗体被纯化。在两种血清中，它们主要位于IgG1中，但也存在于IgG2中。纯化的抗体特异性凝集致敏的绵羊红细胞，并通过间接免疫荧光与L15细胞反应，但不与AKR胸腺细胞反应。提示在导致肿瘤增强或排斥的机制中涉及两种性质不同的体液免疫反应。
